MENLO PARK, Calif., May 16, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, addressed a major ob-gyn meeting this weekend and encouraged the assessment of molecular iodine as a non-hormonal treatment for pain associated with fibrocystic breast condition (FBC) and a viable alternative to the current standard of care.
A presentation to the Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in Washington, D.C. discussed scientific literature that shows most women with FBC-related breast discomfort may experience a reduction in symptoms after taking molecular iodine.
Dr. Lee Shulman, chairman of BioPharmX's Women's Breast Health Medical Advisory Board, and AnnaMarie Daniels, executive vice president of regulatory and clinical affairs at the company, shared information about a multi-center study which BioPharmX is conducting to evaluate the safety, tolerability and efficacy of molecular iodine as a treatment for cyclic breast pain.
The company's existing molecular iodine product, Violet® iodine, is commercially available in the United States. The company is also currently conducting a Phase 4 multicenter clinical trial in women with moderate to severe FBC is designed to expand claims.
Title: "Molecular Iodine (I2) as a non-hormonal treatment for fibrocystic breast pain in premenopausal women"
Location: Washington Convention Center, room 146 A
Date: Sunday, May 15
Time: 10:00 a.m. Eastern Daylight Time
"The current standard of care for FBC-related breast pain treats the condition with hormones, lifestyle changes or analgesics. While hormones are helpful in reducing breast pain, they often result in adverse side effects," said Dr. Shulman, who heads Clinical Genetics in the Department of Obstetrics and Gynecology at Northwestern University's Feinberg School of Medicine in Chicago. "Our review of literature shows that adequate daily supplementation with molecular iodine can significantly improve the quality of life for women."
FBC affects at least 70 percent of premenopausal women. The condition occurs when repeated hormonal exposure accelerates cell division, often resulting in the formation of cysts, fibrous tissue and chronic inflammation.
ACOG's annual meeting attracts thousands of leading women's health experts to share the latest scientific information to benefit patients.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the success of the commercialization of VI2OLET iodine, the conclusion of BioPharmX's Phase 4 study of the company's Violet® molecular iodine supplement, the success of daily molecular iodine supplementation and expansion of claims. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX and Violet are registered trademarks of BioPharmX, Inc. All other products or name brands are trademarks of their respective holders.
For further information:
Senior Manager, Marketing & Communications
firstname.lastname@example.org, (650) 889-5030
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biopharmx-presents-at-american-congress-of-obstetricians-and-gynecologists-acog-suggesting-molecular-iodine-may-be-effective-non-hormonal-treatment-for-fbc-300268782.html
SOURCE BioPharmX Corporation